English

Delivery from RISE - Lumito proceeds to make optimizations on its own account

Report this content

On behalf of Lumito, RISE has developed protocols for development of reagents for tissue staining based on UCNPs (UpConverting NanoParticles). The stained tissue samples are scanned with Lumitos scanner to obtain high-contrast imaging without background information.

RISE delivered the results of the development effort at the end of June. During spring, Lumito has established a laboratory capacity of its own, with a high level of expertise in functionalization of upconverting nanoparticles; the final optimization will now be conducted on the Company's own account. This is consistent with the Company's strategy to gradually build up its own organization possessing the skills and capacity required to continue development and management of its current and future products.

The objective is for the reagents and scanner to be completed and ready for verification and external validation by Q3.

– We are pleased that we now have the internal competence and capacity in place to be able to take over the final optimization from RISE, and that we can continue to develop novel products in this area as well, says Stefan Nilsson, CEO of Lumito, who is looking forward to the product's upcoming verification and validation phase.

 

For more information, please contact:

Lumito AB (publ), CEO Stefan Nilsson, e-mail: sn@lumito.se. 
Phone +46 767 78 59 05

 

This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted, for publication, through the agency of the contact person set out above, on 3 July 2020 at 10:00. 

The share is traded on the Nordic Growth Market, NGM SE, under the ticker LUMITO. The mentor is G&W Fondkommission, telephone: +468-503 000 50.


Lumito specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on 

digital pathology. www.lumito.se

Tags:

Lumito tissuediagnostics digitalpathology Her2-UCNP-reagens UCNP highcontrastimagingwithoutbackgroundsignal revolutionary tissuediagnostics

Subscribe

Documents & Links

Quick facts

RISE delivered the results of the development effort at the end of June. During spring, Lumito has established a laboratory capacity of its own, with a high level of expertise in functionalization of upconverting nanoparticles; the final optimization will now be conducted on the Company's own account. This is consistent with the Company's strategy to gradually build up its own organization possessing the skills and capacity required to continue development and management of its current and future products. The objective is for the reagents and scanner to be completed and ready for verification and external validation by Q3.
Tweet this

Quotes

We are pleased that we now have the internal competence and capacity in place to be able to take over the final optimization from RISE, and that we can continue to develop novel products in this area as well.
Stefan Nilsson, CEO of Lumito who is looking forward to the product's upcoming verification and validation phase